Cadila gets US OK for cholesterol lowering pravastatin
MUMBAI, May 7 (Reuters) - The U.S. Food and Drug Administration has approved Cadila Healthcare Ltd's (CADI.BO: Quote, Profile, Research) cholesterol-fighter pravastatin sodium tablets in various strengths, the regulator's Web site showed on Wednesday.
The U.S. agency also tentatively approved the Indian drug maker's losartan potassium-hydrochlorothiazide tablets used to lower high blood pressure. (Reporting by Bharghavi Nagaraju; Editing by Ramya Venugopal)
© Thomson Reuters 2009 All rights reserved
Dubai Debt Fears
Banks outside the Gulf played down their exposure to Dubai debt, after fears the emirate could default and even derail world economic recovery prompted a sell-off in global markets. Full Article | Slideshow
India Investment Summit 2009
Top executives and bankers discuss their own plans and the broader opportunities and challenges for India. Full Coverage
India
US
UK
